Full Press Release Details
2021Exhibit 99.1 Transforming radiotherapy for patients with cancer April 2021
Forward-Looking Statements Certain information contained in this
presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera's own internal estimates and research. While Galera believes
these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party
sources. While Galera believes its internal research is reliable, such research has not been verified by any independent source. This presentation contains "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future
plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position,
business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential of current and prospective product candidates, plans and timing for the commencement of and the release of data from clinical trials, our plans to
prepare for commercialization and a US launch, the anticipated direct and indirect impact of COVID-19 on Galera's business and operations, planned clinical trials and preclinical activities, potential product approvals and related commercial
opportunity, current and prospective collaborations, and timing and likelihood of success, plans and objectives of management for future operations, are forward-looking statements. The words "may," "will,"
"should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict,"
"potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The
information in this presentation, including without limitation the forward-looking statements contained herein, represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward-looking
statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not
plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements. The forward-looking statements in this presentation involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, our reliance on third parties over which we may not always have full control, and
other important risks and uncertainties that are described in Galera's Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities Exchange Commission (SEC) and Galera's other filings with the SEC. New
risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Whenever the Company uses the terms "transform radiotherapy" or "transforming radiotherapy" in
this presentation, it is referring to its mission statement. 2Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys
and other data obtained from third-party sources and Galera's own internal estimates and research. While Galera believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes
no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Galera believes its internal research is reliable, such research has not been verified by any independent source.
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead,
they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts
contained in this presentation, including statements regarding future results of operations and financial position, business strategy, the safety, efficacy, regulatory and clinical progress, and therapeutic potential of current and prospective
product candidates, plans and timing for the commencement of and the release of data from clinical trials, our plans to prepare for commercialization and a US launch, the anticipated direct and indirect impact of COVID-19 on Galera's business and
operations, planned clinical trials and preclinical activities, potential product approvals and related commercial opportunity, current and prospective collaborations, and timing and likelihood of success, plans and objectives of management for
future operations, are forward-looking statements. The words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. The information in this presentation, including without limitation the forward-looking statements contained herein, represent our views as of
the date of this presentation. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to
place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events,
changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The forward-looking statements in this presentation involve risks and uncertainties that
could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory
approval process, our reliance on third parties over which we may not always have full control, and other important risks and uncertainties that are described in Galera's Annual Report on Form 10-K for the year ended December 31, 2020 filed
with the U.S. Securities Exchange Commission (SEC) and Galera's other filings with the SEC. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Whenever the
Company uses the terms "transform radiotherapy" or "transforming radiotherapy" in this presentation, it is referring to its mission statement. 2
Toxicity Transforming radiotherapy by reducing side effects and
increasing anti-cancer efficacy Over 50% of Cancer Patients Receive Radiotherapy 3 EfficacyToxicity Transforming radiotherapy by reducing side effects and increasing anti-cancer efficacy Over 50% of Cancer Patients Receive Radiotherapy 3
Toxicity REDUCING TOXICITY In radiotherapy Galera shifts the balance
from normal tissue-damaging high levels of superoxide . 4Toxicity REDUCING TOXICITY In radiotherapy Galera shifts the balance from normal tissue-damaging high levels of superoxide . 4
W HI L E I NCRE A S I NG E F F I CA CY to potentially
tumor-toxic high levels of hydrogen peroxide. 5 Efficacy W HI L E I NCRE A S I NG E F F I CA CY to potentially tumor-toxic high levels of hydrogen peroxide. 5 Efficacy
Transforming Radiotherapy Reducing Increasing Large Market IMRT Toxicity
SBRT Efficacy Opportunities In Phase 3 with Breakthrough Encouraging Survival Data High Unmet Medical Need & Therapy Designation in Pancreatic Cancer Trial Limited Therapeutic Options Severe Oral Mucositis Pancreatic Cancer Radiotherapy needed
by over In Head & Neck Cancer Locally Advanced half of patients with cancer Esophagitis Lung Cancer Galera building US commercial in Lung Cancer Locally Advanced team for Avasopasem Launch 6Transforming Radiotherapy Reducing Increasing Large
Market IMRT Toxicity SBRT Efficacy Opportunities In Phase 3 with Breakthrough Encouraging Survival Data High Unmet Medical Need & Therapy Designation in Pancreatic Cancer Trial Limited Therapeutic Options Severe Oral Mucositis Pancreatic Cancer
Radiotherapy needed by over In Head & Neck Cancer Locally Advanced half of patients with cancer Esophagitis Lung Cancer Galera building US commercial in Lung Cancer Locally Advanced team for Avasopasem Launch 6
Robust Pipeline Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Head
& Neck ROMAN: Avasopasem vs. Placebo Topline Data: 2H 2021 IMRT induced Cancer Severe Oral 1 Mucositis EUSOM: Avasopasem Topline Data: 2H 2021 IMRT induced Lung AESOP: Avasopasem Topline Data: 1H 2022 2 Esophagitis Cancer SBRT GRECO-1: GC4711
vs. Placebo Initial Data: 1H 2022 3 Combo Pancreatic Pilot: GC4419 vs. Placebo Final Data: 2H 2021 SBRT Cancer 4 Combo GRECO-2: GC4711 vs. Placebo Initiate Trial: 1H 2021 Hospitalized Pilot: GC4419 vs. Placebo Topline Data: 1H 2021 COVID-19 Patients
(1) EUSOM is a single-arm multi-center trial evaluating the safety and efficacy of avasopasem in patients with HNC in Europe (2) Phase 2a trial in patients with lung cancer building on avasopasem safety and tolerability findings from SOM trials in
patients with HNC (3) Trial to assess anti-cancer efficacy of SBRT +/- GC4711; subsequently, intend to assess anti-cancer efficacy of SBRT and checkpoint inhibitor +/- GC4711 (4) The first SBRT combination trial used GC4419 (avasopasem).
Observations from this pilot trial have been used to guide development of GC4711 to assess anti-cancer efficacy in combination with SBRT 7Robust Pipeline Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Head & Neck ROMAN: Avasopasem vs.
Placebo Topline Data: 2H 2021 IMRT induced Cancer Severe Oral 1 Mucositis EUSOM: Avasopasem Topline Data: 2H 2021 IMRT induced Lung AESOP: Avasopasem Topline Data: 1H 2022 2 Esophagitis Cancer SBRT GRECO-1: GC4711 vs. Placebo Initial Data: 1H 2022 3
Combo Pancreatic Pilot: GC4419 vs. Placebo Final Data: 2H 2021 SBRT Cancer 4 Combo GRECO-2: GC4711 vs. Placebo Initiate Trial: 1H 2021 Hospitalized Pilot: GC4419 vs. Placebo Topline Data: 1H 2021 COVID-19 Patients (1) EUSOM is a single-arm
multi-center trial evaluating the safety and efficacy of avasopasem in patients with HNC in Europe (2) Phase 2a trial in patients with lung cancer building on avasopasem safety and tolerability findings from SOM trials in patients with HNC (3) Trial
to assess anti-cancer efficacy of SBRT +/- GC4711; subsequently, intend to assess anti-cancer efficacy of SBRT and checkpoint inhibitor +/- GC4711 (4) The first SBRT combination trial used GC4419 (avasopasem). Observations from this pilot trial have
been used to guide development of GC4711 to assess anti-cancer efficacy in combination with SBRT 7
Toxicity Reducing IMRT Toxicity 8Toxicity Reducing IMRT Toxicity
Randomized 1:1:1 223 Patient Phase 2b Trial - Robust Results
Randomized Placebo-Controlled Severe Oral Mucositis (SOM) Trial Avasopasem 90mg x 7 weeks R Avasopasem 30mg x 7 weeks Placebo x 7 weeks Stratification Tumor HPV status: + / - Cisplatin schedule: qwk / q3wk Tumor Outcomes Population
Treatment Endpoints Survival (OS, PFS) Locoregional control (LRC) Patients with Head & Neck Avasopasem 90mg, 30mg, Primary: Reduction in SOM Distant Metastases Free (DMF) Cancer (locally advanced)
or placebo duration WHO Grading Scale: Receiving standard IMRT 60-minute IV infusion just Secondary: Reduction in and cisplatin over 7 weeks before IMRT SOM incidence & severity 1 2 3 4 No ulcers Ulcers Ulcers Ulcers
Erythema & Able to eat Require Unable to soreness solid diet liquid diet eat or drink 9Randomized 1:1:1 223 Patient Phase 2b Trial - Robust Results Randomized Placebo-Controlled Severe Oral Mucositis (SOM) Trial Avasopasem 90mg x 7 weeks R
Avasopasem 30mg x 7 weeks Placebo x 7 weeks Stratification Tumor HPV status: + / - Cisplatin schedule: qwk / q3wk Tumor Outcomes Population Treatment Endpoints Survival (OS, PFS) Locoregional control (LRC)
Patients with Head & Neck Avasopasem 90mg, 30mg, Primary: Reduction in SOM Distant Metastases Free (DMF) Cancer (locally advanced) or placebo duration WHO Grading Scale: Receiving standard IMRT 60-minute
IV infusion just Secondary: Reduction in and cisplatin over 7 weeks before IMRT SOM incidence & severity 1 2 3 4 No ulcers Ulcers Ulcers Ulcers Erythema & Able to eat Require Unable to soreness solid diet liquid diet eat or drink
Consistent and Encouraging Results Across SOM Endpoints SOM Incidence
SOM Duration SOM Severity Reduction in Reduction in Reduction in incidence median days incidence of 34% 47% 92% Grade 4 70% 20 30% 18 60% 25% 16 50% 14 p=0.009* 20% 12 40% p=0.045* 10 15% 30% 8 10% 20% 6 4 10% p=0.024 5% 2 0% 0 0% Placebo 30mg 90mg
Placebo 30mg 90mg Placebo 30mg 90mg Intent-To-Treat (ITT) Population *Secondary endpoints (incidence and severity) have nominal p values compared to placebo 10Consistent and Encouraging Results Across SOM Endpoints SOM Incidence SOM Duration SOM
Severity Reduction in Reduction in Reduction in incidence median days incidence of 34% 47% 92% Grade 4 70% 20 30% 18 60% 25% 16 50% 14 p=0.009* 20% 12 40% p=0.045* 10 15% 30% 8 10% 20% 6 4 10% p=0.024 5% 2 0% 0 0% Placebo 30mg 90mg Placebo 30mg 90mg
Placebo 30mg 90mg Intent-To-Treat (ITT) Population *Secondary endpoints (incidence and severity) have nominal p values compared to placebo 10
Avasopasem Efficacy Significantly Better than Placebo PLACEBO Arm (45
of 74 Pts had 1 visit with SOM) 90MG Avasopasem Arm (35 of 76 Pts had 1 visit with SOM) RADIOTHERAPY TREATMENT PERIOD FOLLOW UP POST THERAPY RADIOTHERAPY TREATMENT PERIOD FOLLOW UP POST THERAPY 90 mg Avasopasem 34% Less
Incidence SOM 47% Less Grade 4 OM Grade 3 92% Shorter Duration SOM Grade 4 Delayed Onset of SOM 11Avasopasem Efficacy Significantly Better than Placebo PLACEBO Arm (45 of 74 Pts had 1 visit with SOM) 90MG Avasopasem
Arm (35 of 76 Pts had 1 visit with SOM) RADIOTHERAPY TREATMENT PERIOD FOLLOW UP POST THERAPY RADIOTHERAPY TREATMENT PERIOD FOLLOW UP POST THERAPY 90 mg Avasopasem 34% Less Incidence SOM 47% Less Grade 4 OM Grade 3 92%
Shorter Duration SOM Grade 4 Delayed Onset of SOM 11
Radiotherapy Efficacy Results Maintained Over Two Years 100% 90% 91%
91% 91% 90% 89% 89% 87% 86% 85% 80% 77% 77% 76% 70% 60% 50% 40% 30% 20% 10% 0% Overall Survival (OS) Progression-Free Survival (PFS) Locoregional Control (LRC) Free of Distant Mets (DMF) PBO 30 mg 90 mg Final ITT Analysis; 2-Year Follow-Up
12Radiotherapy Efficacy Results Maintained Over Two Years 100% 90% 91% 91% 91% 90% 89% 89% 87% 86% 85% 80% 77% 77% 76% 70% 60% 50% 40% 30% 20% 10% 0% Overall Survival (OS) Progression-Free Survival (PFS) Locoregional Control (LRC) Free of Distant
Mets (DMF) PBO 30 mg 90 mg Final ITT Analysis; 2-Year Follow-Up 12
Safety Results Comparable to Placebo Avasopasem Generally Well
Tolerated Most Frequent AEs Placebo 30 mg 90 mg Avasopasem Avasopasem (any grade) (n=72) (n=73) (n=72) 100 Lymphopenia 89% 92% 88% 99% 97% 97% 90 95% 95% 94% Nausea 75% 68% 82% 80 Fatigue 69% 60% 65% 70 60 Oropharyngeal pain 64% 63% 61% 50 50%
Constipation 53% 59% 64% 45% 45% 40 Radiation skin injury 47% 51% 53% 30 20 Vomiting 47% 52% 49% 10 1 1 1 Dysgeusia (taste) 49% 55% 43% 0 Dysphagia 43% 42% 47% Grade 2 or worse Grade 3 or worse Grade 4 or 5 Grade 5 (fatal) Weight decreased 35% 40%
44% Placebo (n=72) 30 mg GC4419 (n=73) 90 mg GC4419 (n=72) Oral candidiasis 29% 45% 43% Leukopenia 39% 37% 39% 13Safety Results Comparable to Placebo Avasopasem Generally Well Tolerated Most Frequent AEs Placebo 30 mg 90 mg Avasopasem Avasopasem
(any grade) (n=72) (n=73) (n=72) 100 Lymphopenia 89% 92% 88% 99% 97% 97% 90 95% 95% 94% Nausea 75% 68% 82% 80 Fatigue 69% 60% 65% 70 60 Oropharyngeal pain 64% 63% 61% 50 50% Constipation 53% 59% 64% 45% 45% 40 Radiation skin injury 47% 51% 53% 30 20
Vomiting 47% 52% 49% 10 1 1 1 Dysgeusia (taste) 49% 55% 43% 0 Dysphagia 43% 42% 47% Grade 2 or worse Grade 3 or worse Grade 4 or 5 Grade 5 (fatal) Weight decreased 35% 40% 44% Placebo (n=72) 30 mg GC4419 (n=73) 90 mg GC4419 (n=72) Oral candidiasis
29% 45% 43% Leukopenia 39% 37% 39% 13
Randomized 3:2 450 Patient Phase 3 Trial - Results this Year
Avasopasem 90mg x 7 weeks Randomized Placebo-Controlled Severe Oral Mucositis Trial R Placebo x 7 weeks Stratification Surgery status: + / - before Rx Cisplatin schedule: qwk / q3wk Tumor Outcomes Population Treatment Endpoints
Survival (OS, PFS) Locoregional control (LRC) Patients with Head & Neck Avasopasem 90mg or Primary: Reduction in SOM Distant Metastases Free (DMF) Cancer (locally advanced) placebo incidence WHO
Grading Scale: Receiving standard IMRT 60-minute IV infusion just Secondary: Reduction in and cisplatin over 7 weeks before IMRT SOM duration & severity 1 2 3 4 No ulcers Ulcers Ulcers Ulcers Erythema & Able to eat
Require Unable to soreness solid diet liquid diet eat or drink 14Randomized 3:2 450 Patient Phase 3 Trial - Results this Year Avasopasem 90mg x 7 weeks Randomized Placebo-Controlled Severe Oral Mucositis Trial R Placebo x 7 weeks
Stratification Surgery status: + / - before Rx Cisplatin schedule: qwk / q3wk Tumor Outcomes Population Treatment Endpoints Survival (OS, PFS) Locoregional control (LRC) Patients with Head & Neck
Avasopasem 90mg or Primary: Reduction in SOM Distant Metastases Free (DMF) Cancer (locally advanced) placebo incidence WHO Grading Scale: Receiving standard IMRT 60-minute IV infusion just Secondary: Reduction
in and cisplatin over 7 weeks before IMRT SOM duration & severity 1 2 3 4 No ulcers Ulcers Ulcers Ulcers Erythema & Able to eat Require Unable to soreness solid diet liquid diet eat or drink 14
SOM Market OpportunitySOM Market Opportunity
Head and Neck Cancer - Large Market Opportunity Severe Oral
Mucositis is most burdensome side effect - 70% get SOM 650,000 Global Head & Neck Cancer Incidence Initial 65,630 Target US Patients Diagnosed each year Population 42,000 US Patients at Risk for RT-related SOM Locally advanced HNC curable